4004 ESC Guidelines label use of medication should be limited to situations where it is in
the patient's interest to do so, with regard to the quality, safety, and efficacy of care, and only …

• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Background: Filamin C truncating variants (FLNCtv) cause a form of arrhythmogenic
cardiomyopathy: the mode of presentation, natural history, and risk stratification of FLNCtv …

Aims To study the impact of genotype on the performance of the 2019 risk model for
arrhythmogenic right ventricular cardiomyopathy (ARVC). Methods and results The study …

Purpose Genetic testing has advanced significantly since the publication of the 2011
HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the …

There is increasing evidence regarding the prevalence of genetic cardiomyopathies, for
which arrhythmias may be the first presentation. Ventricular and atrial arrhythmias …

In the early nineties, few years before the birth of Europace, the clinical and scientific world
of familial arrhythmogenic conditions was revolutionized by the identification of the first …

Abstract Purpose of Review Arrhythmogenic cardiomyopathy (ACM) is a genetic disease
characterized by life-threatening ventricular arrhythmias and sudden cardiac death (SCD) in …

Sudden cardiac death (SCD) is responsible for several millions of deaths every year and
remains a major health problem. To reduce this burden, diagnosing and identification of …

Many previously unexplained life-threatening ventricular arrhythmias and sudden cardiac
deaths (SCDs) in young individuals are now recognized to be genetic in nature and are …